Clinical Trial Update: A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating two oral doses of GSK557296 for safety, tolerability, pharmacokinetics, and pharmacodynamics in men with premature ejaculation has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• GSK557296 (GSK557296)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Premature Ejaculation | Phase 2 | Status: COMPLETED | Results posted: 2017-09-12